Hoe verhoudt 0TDF's PE Ratio zich tot zijn concurrenten?

0TDF is een goede waarde op basis van zijn Price-To-Earnings Ratio (19x) vergeleken met het gemiddelde van gelijken (22.6x).

Hoe verhoudt 0TDF's PE Ratio zich tot andere bedrijven in de European Pharmaceuticals industrie?

0TDF is een goede waarde op basis van de Price-To-Earnings -ratio ( 19 x) vergeleken met het UK Pharmaceuticals -industriegemiddelde ( 31.4 x).

Wat is 0TDF's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

0TDF is een goede waarde op basis van de Price-To-Earnings -ratio ( 19 x) vergeleken met de geschatte eerlijke Price-To-Earnings -ratio ( 37 x).

Wat is de reële prijs van 0TDF als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

0TDF ( $35.55 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( $101.87 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Roche Holding (LSE:0TDF) - Aandelenkoers, Nieuws & Analyse

0TDF Overzicht aandelen

Roche Holding AG is actief in de farmaceutische en diagnostische sector in Europa, Noord-Amerika, Latijns-Amerika, Azië, Afrika, Australië en Oceanië. Meer informatie

0TDF fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	5/6

Beloningen

Verhandeld tegen 65.1% onder onze schatting van de reële waarde

De winst zal naar verwachting met 11.15% per jaar groeien

Betaalt een betrouwbaar dividend van 3.79%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Heeft een hoog schuldenniveau

Grote eenmalige posten die de financiële resultaten beïnvloeden

Roche Holding AG Concurrenten

AstraZeneca

LSE:AZN

UK£162.4b

GSK

LSE:GSK

UK£54.9b

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

Novartis

SWX:NOVN

CHF 183.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Roche Holding
Historische aandelenkoersen
Huidige aandelenkoers	CHF 35.55
52 Week Hoogtepunt	CHF 41.85
52 Week Laag	CHF 29.27
Bèta	0.15
11 maand verandering	-12.40%
3 maanden verandering	-15.05%
1 Jaar Verandering	5.49%
33 jaar verandering	-27.20%
5 jaar verandering	-6.89%
Verandering sinds IPO	15.09%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0TDF	GB Pharmaceuticals	GB Markt
7D	0.4%	5.0%	2.2%
1Y	5.5%	2.5%	8.8%

Rendement versus industrie: 0TDF overtrof de UK Pharmaceuticals industrie, die het afgelopen jaar een rendement 2.5 % opleverde.

Rendement versus markt: 0TDF presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 8.8 % opleverde.

Prijsvolatiliteit

Is 0TDF's price volatile compared to industry and market?
0TDF volatility
0TDF Average Weekly Movement	4.0%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: 0TDF heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van 0TDF is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG is actief in de farmaceutische en diagnostische sector in Europa, Noord-Amerika, Latijns-Amerika, Azië, Afrika, Australië en Oceanië. Het bedrijf biedt farmaceutische producten aan in de therapeutische gebieden bloedarmoede, bloed- en vaste tumoren, dermatologie, hemofilie, ontstekings- en autoimmuunziekten, neurologische aandoeningen, oogheelkunde, ademhalingsaandoeningen en transplantatie. Het ontwikkelt ook producten voor verschillende therapeutische gebieden.

Roche Holding AG Samenvatting

Hoe verhouden de winst en inkomsten van Roche Holding zich tot de beurswaarde?
0TDF fundamentele statistieken
Marktkapitalisatie	US$230.29b
Inkomsten(TTM)	US$11.98b
Inkomsten(TTM)	US$68.36b

19.0x

Koers/Winstverhouding

3.3x

P/S-verhouding

Is 0TDF overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0TDF resultatenrekening (TTM)
Inkomsten	CHF 60.58b
Kosten van inkomsten	CHF 15.43b
Brutowinst	CHF 45.16b
Overige uitgaven	CHF 34.54b
Inkomsten	CHF 10.62b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	13.33
Brutomarge	74.54%
Nettowinstmarge	17.53%
Schuld/Eigen Vermogen Verhouding	104.8%

Hoe presteerde 0TDF op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.8%

Huidig dividendrendement

72%

Uitbetalingsratio

0TDF Overzicht aandelen

Beloningen

Risicoanalyse

Roche Holding AG Concurrenten

LSE:AZN

UK£162.4b

LSE:GSK

UK£54.9b

LSE:HIK

UK£4.4b

SWX:NOVN

CHF 183.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Recent updates

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran